Daily Stock Analysis, EDIT, Editas Medicine Inc, priceseries

Editas Medicine Inc. Daily Stock Analysis
Stock Information
Open
61.00
Close
63.20
High
63.54
Low
59.23
Previous Close
61.00
Daily Price Gain
2.20
YTD High
99.95
YTD High Date
Jan 8, 2021
YTD Low
29.35
YTD Low Date
May 11, 2021
YTD Price Change
-8.39
YTD Gain
-11.72%
52 Week High
99.95
52 Week High Date
Jan 8, 2021
52 Week Low
27.01
52 Week Low Date
Oct 2, 2020
52 Week Price Change
29.30
52 Week Gain
86.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 14. 2017
18.86
Feb 27. 2017
23.16
8 Trading Days
22.79%
Link
LONG
Jun 16. 2017
16.28
Jun 29. 2017
17.26
9 Trading Days
6.02%
Link
LONG
Nov 15. 2017
24.34
Dec 5. 2017
27.53
13 Trading Days
13.09%
Link
LONG
Dec 21. 2017
26.71
Jan 8. 2018
29.47
10 Trading Days
10.33%
Link
LONG
May 4. 2018
33.00
May 18. 2018
35.51
10 Trading Days
7.61%
Link
LONG
Mar 28. 2019
23.63
Apr 11. 2019
25.54
10 Trading Days
8.08%
Link
LONG
Nov 12. 2019
22.32
Dec 11. 2019
29.71
20 Trading Days
33.13%
Link
LONG
Jun 15. 2020
28.94
Jun 24. 2020
31.13
7 Trading Days
7.58%
Link
LONG
Aug 3. 2020
31.57
Aug 7. 2020
33.51
4 Trading Days
6.13%
Link
LONG
Nov 25. 2020
29.45
Dec 29. 2020
74.94
22 Trading Days
154.48%
Link
LONG
Jun 23. 2021
37.82
Jul 7. 2021
46.25
9 Trading Days
22.28%
Link
LONG
Aug 4. 2021
46.05
Aug 19. 2021
58.82
11 Trading Days
27.72%
Link
Company Information
Stock Symbol
EDIT
Exchange
NasdaqGS
Company URL
http://www.editasmedicine.com
Company Phone
617-401-9000
CEO
Katrine S. Bosley
Headquarters
Massachusetts
Business Address
11 HURLEY ST., CAMBRIDGE, MA 02141
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001650664
About

Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.^ ^ ^

Description

Developing gene editing therapies based on CRISPR/Cas9 technology.